WA-ITRON
18.2.2021 14:47:08 CET | Business Wire | Press release
Itron, Inc. (NASDAQ: ITRI), which is innovating the way utilities and cities manage energy and water, announced that it will host its flagship event, Itron Utility Week (IUW), virtually for smart city and utility leaders in Europe, Middle East and Africa (EMEA) on March 16 and 17, 2021. As the first regional IUW, the two-day event will bring leaders together virtually to share insights and solutions to address pressing challenges and create opportunity, together. To ensure the safety of all attendees in light of the COVID-19 pandemic, the customer-focused event will be completely virtual.
“We are thrilled to introduce this event to EMEA for the first time to bring together industry experts, colleagues and thought leaders to share fresh perspectives and open the door to endless possibilities through innovation,” said Marina Donovan, vice president of global marketing and public affairs at Itron. “For decades, Itron has collaborated with cities, municipalities and utilities in EMEA to provide innovative, long-term energy and water solutions. At IUW EMEA, we look forward to building on this success to create a more resourceful world.”
“This event has been designed to share knowledge and experience and discuss ways of solving issues facing utilities, municipalities and cities in EMEA,” said Andrew Jones, vice president of Sales for EMEA. “I look forward to gathering virtually with industry leaders, utility peers and smart city representatives to share ideas to create a brighter future for ourselves, our businesses and our communities.”
Itron Utility Week EMEA will be offered virtually and at no charge and will be available in English with subtitles in French, German, Spanish and Italian.
What: |
Itron Utility Week EMEA 2021 includes peer-led breakout sessions about technology, trends and best practices; insightful keynotes from industry leaders; engaging and thought-provoking panels; and an interactive product showcase of select Itron solutions. |
|
When: |
March 16-17, 2021 |
|
Where: |
Sessions: Keynote and featured sessions at Itron Utility Week EMEA include:
- Opening Keynote: Tom Deitrich, Itron’s CEO and president, will open the event with Andrew Jones, Itron’s vice president of Sales, to discuss how to deliver better ROI and empower business transformation for utilities and cities.
-
Breakout Sessions:
Tailored breakout sessions provide the opportunity to learn from and have conversations with industry peers and Itron employees who have a firsthand understanding of the issues at play in the sector. Breakout sessions are organized into two tracks: Water Management and Smart City and Utility Solutions. Among the topics that will be covered are:
- Leveraging multi-purpose networks to enable digital communities;
- Reducing non-revenue water through leak detection;
- Quantifying the value and benefits of distributed intelligence;
- Accelerating electric vehicle adoption through grid analytics and charging management; and
- A smart city panel where several city and community experts will share how cities are navigating the pandemic and how connected city infrastructure and services can aid recovery.
To keep up with live updates throughout the conference read updates on the Itron blog and follow Itron and #IUWEMEA on social media. There is no charge to attend and event registration is now open for Itron customers, prospects and partners. For more information about Itron Utility Week EMEA: Empowering Innovation, visit itron.com/iuwemea .
About Itron
Itron enables utilities and cities to safely, securely and reliably deliver critical infrastructure solutions to communities in more than 100 countries. Our portfolio of smart networks, software, services, meters and sensors helps our customers better manage electricity, gas and water resources for the people they serve. By working with our customers to ensure their success, we help improve the quality of life, ensure the safety and promote the well-being of millions of people around the globe. Itron is dedicated to creating a more resourceful world. Join us: www.itron.com .
Itron® is a registered trademark of Itron, Inc. All third-party trademarks are property of their respective owners and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005233/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
